Subgingival Lactobacillus Reuteri as an Adjunct to Non-Surgical Periodontal Therapy in Diabetic Patients (LREUTERI-DM)
Effect of Adjunctive Subgingival Lactobacillus Reuteri in Non-Surgical Periodontal Therapy for Periodontitis in Patients With Diabetes: A Randomized Controlled Clinical Trial
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Periodontitis is a chronic inflammatory disease associated with dysbiotic subgingival biofilms and is strongly influenced by diabetes mellitus. Chronic hyperglycemia may impair immune function and wound healing, resulting in increased periodontal destruction and poorer treatment outcomes. Non-surgical periodontal therapy based on scaling and root planing (SRP) remains the standard treatment; however, residual periodontal pockets may persist after therapy.
Lactobacillus reuteri probiotics have demonstrated antimicrobial, anti-inflammatory, and host-modulatory properties and may enhance periodontal healing. This randomized controlled clinical trial evaluated the adjunctive effects of subgingival administration of a liquid probiotic preparation containing Lactobacillus reuteri in diabetic patients with Stage III Grade B or higher periodontitis.
Forty periodontal sites were randomly allocated to either a test group receiving SRP plus subgingival Lactobacillus reuteri probiotics or a control group receiving SRP plus saline irrigation. A second application was performed at the 1-month visit. Clinical outcomes included plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment level. Glycemic control was evaluated using HbA1c levels, and microbiological analysis was performed using real-time PCR for Porphyromonas gingivalis, Tannerella forsythia, and Fusobacterium nucleatum.
Assessments were conducted at baseline, 1 month, and 3 months. The primary objective was to evaluate changes in clinical outcomes. Secondary objectives included microbiological and glycemic outcomes.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
- Faculty of Dentistry, University of Medicine and Pharmacy at Ho Chi Minh City
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥18 years.
- Diagnosed with diabetes mellitus according to WHO criteria.
- Stage III Grade B periodontitis or higher according to the 2017 AAP/EFP classification.
- At least 15 remaining teeth.
- Periodontal pockets ≥5 mm with bleeding on probing.
- Clinical attachment loss ≥5 mm.
Exclusion Criteria:
- Current smokers.
- Pregnant or lactating women.
- Use of antibiotics or anti-inflammatory medications within 1 month before enrollment.
- Periodontal therapy within the previous 3 months.
- Undergoing orthodontic treatment.
- Presence of pulpal lesions or severe occlusal trauma.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: SRP + Lactobacillus reuteri
Subgingival Lactobacillus reuteri
|
Subgingival administration of liquid Lactobacillus reuteri following scaling and root planing.
The probiotic solution was applied into periodontal pockets at baseline and re-applied after 1 month.
|
|
Comparatore attivo: SRP + Saline
Saline Control
|
Subgingival administration of sterile saline solution following scaling and root planing.
Saline was applied into periodontal pockets at baseline and re-applied after 1 month using the same protocol as the test intervention.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Bleeding on Probing (BOP)
Lasso di tempo: Baseline to 3 months
|
Bleeding on probing was assessed at baseline, 1 month, and 3 months after treatment.
Changes in the percentage of bleeding sites were used to evaluate periodontal inflammation.
|
Baseline to 3 months
|
|
Change in Probing Pocket Depth (PPD)
Lasso di tempo: Baseline to 3 months.
|
Probing pocket depth was measured using a UNC-15 periodontal probe at baseline, 1 month, and 3 months after treatment.
The primary outcome was the change in PPD from baseline to 3 months.
|
Baseline to 3 months.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Clinical Attachment Level (CAL)
Lasso di tempo: Baseline to 3 months.
|
Clinical attachment level (CAL) was measured using a UNC-15 periodontal probe.
Changes in CAL was assessed to evaluate periodontal attachment gain following treatment.
|
Baseline to 3 months.
|
|
Changes in Glycated Hemoglobin (HbA1c)
Lasso di tempo: Baseline, 1 month, and 3 months
|
HbA1c levels were assessed at baseline, 1 month, and 3 months following treatment to evaluate glycemic control.
|
Baseline, 1 month, and 3 months
|
|
Changes in Subgingival Periodontal Pathogens
Lasso di tempo: Baseline to 3 months
|
Quantitative levels of Porphyromonas gingivalis, Tannerella forsythia, Fusobacterium nucleatum were assessed using microbiological analysis.
|
Baseline to 3 months
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Thu Nguyen Ngoc Yen, PhD, Faculty of Dentistry, University of Medicine and Pharmacy at Ho Chi Minh City
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- THS-PERIO-2026-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .